Repositioning Candidate Details
| Candidate ID: | R0024 |
| Source ID: | DB00081 |
| Source Type: | approved; investigational |
| Compound Type: | biotech |
| Compound Name: | Tositumomab |
| Synonyms: | Tositumomab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). |
| CAS Number: | 208921-02-2 |
| Molecular Weight: | |
| DrugBank Indication: | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) |
| DrugBank Pharmacology: | Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells. |
| DrugBank MoA: | Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation. |
| Targets: | B-lymphocyte antigen CD20 antibody; Low affinity immunoglobulin gamma Fc region receptor II-b |
| Inclusion Criteria: | Therapeutic strategy associated |
